Knight Therapeutics Inc. stock has seen mixed performance recently, with a slight decline this week despite some positive company developments.
This week, Knight Therapeutics Inc. (GUD.TO) closed at C$9.75, reflecting a 1.61% decrease over the past week. The company has been in the news for various reasons, including its recent earnings report and financial maneuvers, which have implications for its stock performance.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Knight Therapeutics Inc.
GUD.TO
GUD.TO
Knight Therapeutics Inc.
WealthAwesomeMarket cap
$962.16M
P/E
163.3x
52W high
$10.17
52W low
$5.66
1W change
-1.61%
Beta
0.05
Analyst Price Targets
Based on analyst covering GUD
Wall Street analysts forecast GUD stock price to rise 0.3% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$9.83
+0.3% Upside
Current Price
C$9.80
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GUD's historical volatility
30-Day Vol
23.6%
Annualized
90-Day Vol
30.7%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$11.72
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$10.40 | C$9.59 โ C$11.28 |
| 60 trading days | C$11.04 | C$9.84 โ C$12.39 |
| 90 trading days | C$11.72 | C$10.18 โ C$13.49 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should consider the recent earnings report and repayment of debt as indicators of the company's financial health, while also being mindful of the stock's recent performance relative to its historical range.
Knight Therapeutics Achieves 65.82% YTD Gain
Despite a slight dip this week, Knight Therapeutics has seen a significant year-to-date increase of 65.82%, indicating strong market performance over the long term.
Bull case
Knight Therapeutics has positive earnings growth and is strategically repaying its debt, which could set the stage for future growth. If the company continues to expand its product portfolio successfully, it may see further gains.
Bear case
However, the stock's high P/E ratio and recent price decline raise concerns about overvaluation and whether its recent gains can be sustained.
Recent Price Action
Knight Therapeutics Inc. stock closed at C$9.75, reflecting a 1D change of +0.00% and a weekly decline of 1.61%. Over the past month, the stock has appreciated by 3.38%, contributing to an impressive year-to-date performance of 65.82%.
Company News and Catalysts
Knight Therapeutics has been in the spotlight this week due to several announcements. The company reported record Q1 2026 earnings, driven by portfolio expansion and new product launches. Additionally, Knight has successfully repaid all amounts under its US$100 million revolving credit facility, signaling strong cash flow from operations in both Canada and Latin America. Furthermore, Knight has amended its normal course issuer bid, which could indicate a strategy to manage its share count and enhance shareholder value.
Technical Picture
From a technical standpoint, Knight Therapeutics is currently trading at C$9.75, above its 50-day moving average of C$8.84 (+10.2%) and significantly above its 200-day moving average of C$6.91 (+41.0%). The stock has a 52-week range of C$5.66 to C$10.17, indicating that it has been trading at 91% of its range. With a low beta of 0.05, the stock is considered relatively stable compared to the overall market. However, trading volume has been low, with only 954 shares exchanged recently compared to a 20-day average of 114,446 shares, suggesting decreased investor interest.
Advertisement
